<DOC>
	<DOC>NCT00228462</DOC>
	<brief_summary>This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.</brief_summary>
	<brief_title>Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Stable schizophrenic patients who have provided written informed consent Patients 18 to 65 years old who remain clinically stable after switching to a stable dose of Seroquel (quetiapine). Patients with risk of suicide, other disorders or substance abuse that might interfere with the patient's ability to cooperate, Expected noncompliance to treatment Known diabetes mellitus, Contraindications, Intolerance or nonresponsiveness to Seroquel or other safety issues.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>